- Home
- EXK vs CELC Comparison
EXK vs CELC Comparison
Compare EXK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXK | CELC |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EXK | CELC |
|---|---|---|
| Price | $10.27 | $122.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $13.94 | ★ $107.88 |
| AVG Volume (30 Days) | ★ 8.7M | 661.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $63.94 | N/A |
| Revenue Next Year | $8.76 | $720.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.23 | $9.64 |
| 52 Week High | $15.15 | $127.34 |
Technical Indicators
Market Signals| Indicator | EXK | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 57.50 |
| Support Level | $8.33 | $99.38 |
| Resistance Level | $10.31 | N/A |
| Average True Range (ATR) | 0.54 | 5.29 |
| MACD | 0.18 | 0.90 |
| Stochastic Oscillator | 80.59 | 75.39 |
Price Performance
Historical ComparisonAbout EXK Endeavour Silver Corporation (Canada)
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.